Key result
DOAC feasibility for acute PE in Child-Pugh B cirrhosis explored in a case report.
Why the study?
To address whether a direct oral anticoagulant can be used for anticoagulation in a patient with Child-Pugh class B cirrhosis presenting with an acute pulmonary embolism.
Can a direct oral anticoagulant (DOAC) be safely and effectively used for anticoagulation in a patient with cirrhosis and acute pulmonary embolism?
Case Report (n=1)
Can a direct oral anticoagulant (DOAC) be safely and effectively used for anticoagulation in a patient with cirrhosis and acute pulmonary embolism?
This clinical vignette highlights the therapeutic dilemma of using direct oral anticoagulants for venous thromboembolism in patients with cirrhosis and portal hypertension.
Answers are grounded in this paper and cite their sources.
Caution advised for DOACs in Child-Pugh B cirrhosis with PE; case leaves open need for controlled safety data.
A 59-year-old female with Child-Pugh class B cirrhosis attributed to nonalcoholic steatohepatitis complicated by hepatic encephalopathy, portal hypertension with esophageal varices, and thrombocytopenia is seen for management of an acute segmental right lower lobe pulmonary embolism in a clinic. She is hemodynamically stable. Complete blood count is notable for hemoglobin 11.6 g/dL and platelets 80 K/μL. Prothrombin time is 12.6 seconds; partial thromboplastin time, 33.7 seconds; and fibrinogen, 221 mg/dL. She was referred to discuss if a direct oral anticoagulant (DOAC) can be used for anticoagulation. What would you suggest?
No takes yet. Share an insight, caveat, or question.
Afzal et al. (2023) conducted a case report in Pulmonary embolism and cirrhosis (n=1). Direct oral anticoagulant (DOAC) was evaluated. A 59-year-old female with Child-Pugh class B cirrhosis and acute pulmonary embolism was presented to discuss the feasibility of using direct oral anticoagulants for anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: